Why the study?
Does ginsenoside Ro inhibit fibrinogen binding to αIIb/β3 and platelet aggregation in thrombin-induced human platelets?
Does ginsenoside Ro inhibit fibrinogen binding to αIIb/β3 and platelet aggregation in thrombin-induced human platelets?
Answers are grounded in this paper and cite their sources.
Ginsenoside Ro inhibits αIIb/β3-mediated fibrinogen binding and clot retraction in human platelets, suggesting potential as a novel anti-thrombotic compound.
Glycoprotein IIb/IIIa (αIIb/β3) is involved in platelet adhesion, and triggers a series of intracellular signaling cascades, leading to platelet shape change, granule secretion, and clot retraction. In this study, we evaluated the effect of ginsenoside Ro (G-Ro) on the binding of fibrinogen to αIIb/β3. We investigated the effect of G-Ro on regulation of signaling molecules affecting the binding of fibrinogen to αIIb/β3, and its final reaction, clot retraction. We found that G-Ro dose-dependently inhibited thrombin-induced platelet aggregation and attenuated the binding of fibrinogen to αIIb/β3 by phosphorylating cyclic adenosine monophosphate (cAMP)-dependently vasodilator-stimulated phosphoprotein (VASP; Ser157). In addition, G-Ro strongly abrogated the clot retraction reflecting the intensification of thrombus. We demonstrate that G-Ro is a beneficial novel compound inhibiting αIIb/β3-mediated fibrinogen binding, and may prevent platelet aggregation-mediated thrombotic disease.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: